Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anitocabtagene autoleucel versus standard-of-care therapy for relapsed/refractory multiple myeloma
2024-511188-26-00Phase 3Authorised
- Sponsor
- Kite Pharma
- Start
- Dec 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Anitocabtagene autoleucel with Standard of care therapy (2 arms). Primary endpoints: Progression-free survival and MRD-negative complete response rate at 9 months. Planned start Dec 2024; status: authorised.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511188-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511188-26-00.